Solid Biosciences Inc (SLDB)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

141 PORTLAND STREET, FIFTH FLOOR CAMBRIDGE, MA 02139

Solid Biosciences Inc. operates as a biotechnology company. The Company develops therapies and devices for the patients with duchenne muscular dystrophy. Solid Biosciences serves clients in the United States.

Data as of 2020-11-22
Market Cap194.042 Million Shares Outstanding60.449 Million Avg 30-day Volume850.962 Thousand
P/E Ratio-1.6 Dividend Yield EPS-2.04
Price/Sales Price cash flow ratio Price free cash flow ratio-2.4
Book Value0.37 Price to Tangible Book8.73 Alpha0.01
Short Interest Ratio % Short Interest to Float R-squared0.016213
BETA0.8534 52-week High/Low6.1 / 1.93 Stddev0.35558
View SEC Filings from SLDB instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 1 -100.0% 0 (0.0%) 0 (0.0%)
Funds Holding: 63 67 -5.97% 23 (1.51%) 24 (1.56%) -4.17%
13F shares: 25.824 Million 26.783 Million -3.58% 14.007 Million 14.207 Million -1.41%
% Ownership 56.0151 58.0948 -3.58% 30.3831 30.8174 -1.41%
New Positions: 7 10 -30.0% 3 3 0.0%
Increased Positions 17 22 -22.73% 7 12 -41.67%
Closed Positions 11 16 -31.25% 4 5 -20.0%
Reduced Positions 24 21 14.29% 7 5 40.0%
Total Calls 4.4 Thousand 58.45 Thousand -92.47% 35.6 Thousand
Total Puts 1.6 Thousand 46.762 Thousand -96.58%
PUT/CALL Ratio 0.36 0.8 -55.0% 0.0
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding SLDB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SLDB BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ULTRAGENYX PHARMACEUTICAL INC.

  • 10% Owner
7,825,797 2020-10-22 1

GANOT ILAN CEO & PRESIDENT

  • Officer
  • Director
1,442,404 2020-08-12 7

MORRIS CARL ASHLEY CHIEF SCIENTIFIC OFFICER

  • Officer
290,959 2020-07-27 4

ZIOLKOWSKI JENNIFER LYNN CFO, TREASURER & ASST. SECY

  • Officer
327,609 2020-07-27 4

SCHNEIDER JOEL SOLOMON ZEV CHIEF TECHNOLOGY OFFICER

  • Officer
284,115 2020-07-27 4

HERSCHA LYNETTE CHIEF LEGAL OFFICER

  • Officer
160,859 2020-07-27 4

STONE ADAM LEO

  • Director
0 2020-06-16 1

SHAH RAJEEV M.

  • Director
0 2020-06-16 1

HUFFINES ROBERT LUTHER

  • Director
0 2020-06-16 1

SULLIVAN LYNNE MARIE

  • Director
0 2020-06-16 1

ARNOLD MATTHEW BENNETT

  • Director
0 2020-06-16 1

KOPPEL ADAM

  • Director
0 2020-06-16 1

FREED MARTIN I

  • Director
0 2020-06-16 1

PERCEPTIVE ADVISORS LLC

EDELMAN JOSEPH

  • Director
  • 10% Owner
0 2020-06-16 1

NAGENDRAN SUKUMAR

  • Director
0 2020-06-16 1

SMITH IAN F

  • Director
0 2020-06-16 3

ZARUR JUAN ANDREY

  • Director
0 2020-01-02 1

PERCEPTIVE ADVISORS LLC

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

EDELMAN JOSEPH

  • Director
  • 10% Owner
6,749,803 2019-07-25 1

BOXER CAPITAL, LLC

  • 10% Owner
3,473,272 2019-03-26 0

BOXER CAPITAL, LLC

BOXER ASSET MANAGEMENT INC.

BRASLYN LTD.

LEWIS JOSEPH

MVA INVESTORS, LLC

  • 10% Owner
3,964,970 2019-03-04 0

AMORRORTU PEDRO ALVARO CHIEF OPERATING OFFICER

  • Officer
0 2019-01-23 0

QUIROZ JORGE ARMANDO CHIEF MEDICAL OFFICER

  • Officer
0 2019-01-23 0

HAYEEM GILAD DAVID

  • 10% Owner
No longer subject to file 2018-08-22 0

JPMORGAN CHASE & CO

JPMC STRATEGIC INVESTMENTS II CORP

  • FORMER 10% OWNERFORMER 10% OWNER
No longer subject to file 2018-01-30 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments